Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/38813
Full metadata record
DC FieldValueLanguage
dc.contributor.authorValgimigli, Marco-
dc.contributor.authorFrigoli, Enrico-
dc.contributor.authorVRANCKX, Pascal-
dc.contributor.authorOzaki, Yukio-
dc.contributor.authorMorice, Marie-Claude-
dc.contributor.authorChevalier, Bernard-
dc.contributor.authorOnuma, Yoshinobu-
dc.contributor.authorWindecker, Stephan-
dc.contributor.authorDelorme, Laurent-
dc.contributor.authorKala, Petr-
dc.contributor.authorKedev, Sasko-
dc.contributor.authorAbhaichand, Rajpal K.-
dc.contributor.authorVelchev, Vasil-
dc.contributor.authorDewilde, Willem-
dc.contributor.authorPodolec, Jakub-
dc.contributor.authorLeibundgut, Gregor-
dc.contributor.authorTopic, Dragan-
dc.contributor.authorSchultz, Carl-
dc.contributor.authorStankovic, Goran-
dc.contributor.authorLee, Astin-
dc.contributor.authorJohnson, Thomas-
dc.contributor.authorTonino, Pim A. L.-
dc.contributor.authorKlotzka, Aneta-
dc.contributor.authorLesiak, Maciej-
dc.contributor.authorLopes, Renato D.-
dc.contributor.authorSmits, Pieter C.-
dc.contributor.authorHeg, Dik-
dc.date.accessioned2022-10-26T06:42:49Z-
dc.date.available2022-10-26T06:42:49Z-
dc.date.issued2022-
dc.date.submitted2022-10-20T11:17:39Z-
dc.identifier.citationJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 80 (8) , p. 766 -778-
dc.identifier.urihttp://hdl.handle.net/1942/38813-
dc.description.abstractBACKGROUND Nonadherence to antiplatelet therapy after percutaneous coronary intervention (PCI) is common, even in clinical trials. OBJECTIVES The purpose of this study was to investigate the impact of nonadherence to study protocol regimens in the MASTER DAPT (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen) trial. METHODS At 1-month after PCI, 4,579 high bleeding risk patients were randomized to single antiplatelet therapy (SAPT) for 11 months (or 5 months in patients on oral anticoagulation [OAC]) or dual antiplatelet therapy (DAPT) for >= 2 months followed by SAPT. Coprimary outcomes included net adverse clinical events (NACE), major adverse cardiac and cerebral events (MACE), and major or clinically relevant nonmajor bleeding (MCB) at 335 days. Inverse probability-ofcensoring weights were used to correct for nonadherence Academic Research Consortium type 2 or 3. RESULTS In total, 464 (20.2%) patients in the abbreviated-treatment and 214 (9.4%) in the standard-treatment groups incurred nonadherence Academic Research Consortium type 2 or 3. At inverse probability-of-censoring weights analyses, NACE (HR: 1.01; 95% CI: 0.88-1.27) or MACE (HR: 1.07; 95% CI: 0.83-1.40) did not differ, and MCB was lower with abbreviated compared with standard treatment (HR: 0.51; 95% CI: 0.60-0.73) consistently across OAC subgroups; among OAC patients, SAPT discontinuation 6 months after PCI was associated with similar MACE and lower MCB (HR: 0.47; 95% CI: 0.22-0.99) compared with SAPT continuation. CONCLUSIONS In the MASTER DAPT adherent population, 1-month compared with >= 3-month DAPT was associated with similar NACE or MACE and lower MCB. Among OAC patients, SAPT discontinuation after 6 months was associated with similar MACE and lower MCB than SAPT continuation (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen [MASTER DAPT]; (C) 2022 by the American College of Cardiology Foundation.-
dc.description.sponsorshipThe MASTER DAPT trial is conducted with support from Terumo. The study sponsor, European Cardiovascular Research Institute (ECRI), Rotterdam, the Netherlands, a nonprofit organization, received grant support from Terumo for the conduct of the MASTER DAPT trial. ECRI outsourced to Clinical trial Unit, Bern, Switzerland all statistical analyses of the present paper under a research contract agreement between the 2 institutions. None of the authors received personal or institutional payment for the present paper. Dr Valgimigli has received grants and personal fees from Terumo; and has received personal fees from AstraZeneca, Alvimedica/CID, Abbott Vascular, Daiichi-Sankyo, Bayer, CoreFLOW, Idorsia Pharmaceuticals Ltd, Universität Basel, Department Klinische Forschung, Vifor, Bristol Myers Squibb SA, Biotronik, Boston Scientific, Medtronic, Vesalio, Novartis, Chiesi, and PhaseBio. Dr Heg’s institution, CTU Bern, University of Bern, has a staff policy of not accepting honoraria or consultancy fees; however, CTU Bern is involved in design, conduct, or analysis of clinical studies funded by not-for-profit and for-profit organizations, and in particular, pharmaceutical and medical device companies provide direct funding to some of these studies. Dr Vranckx has received personal fees from Daiichi-Sankyo, Bayer AG, BLS Bering, and AstraZeneca. Dr Ozaki has received grants from Takeda Pharmaceutical Company Ltd, Daiichi-Sankyo Company Ltd, Otsuka Pharmaceutical Company Ltd, and Sanofi. Dr Morice is a shareholder and CEO of CERC and a minor shareholder of Electroducer (a start-up not involved in the MASTER DAPT trial). DrChevalier has received personal fees from Terumo and CERC; and holds stock options in Colibri. Dr Windecker has received grants from Abbott, Amgen, AstraZeneca, Bristol Myers Squibb, Bayer, Biotronik, Boston Scientific, Cardinal Health, CadioValve, CSL Behring, DaiichiSankyo, Edwards Lifesciences, Guerbet, InfraRedx, Johnson and Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sinomed, Terumo, and V-Wave; serves as unpaid advisory board member and/or unpaid member of the steering/executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, Bristol Myers Squibb, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis, but has not received personal payments by pharmaceutical companies ordevice manufacturers; is a member of the steering/executive committee group of several investigator-initiated trials that receive funding by industry without impact on his personal remuneration; is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee; is a member of the Clinical Study Group of the Deutsches Zentrum für Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute; and is chairperson of the ESC Congress Program Committee, former chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor of JACC: Cardiovascular Interventions. Dr Kala has served as a consultant for Boston Scientific; has received research support from Novartis; and has received honoraria from Bayer, Servier, AstraZeneca, Chiesi, and Boehringer Ingelheim. Dr Schultz has received Abbott Vascular. Dr Lopes has received institutional research grants and consulting fees from Bristol Myers Squibb, Pfizer, GlaxoSmithKline, Medtronic PLC, and Sanofi; and has received consulting fees from Amgen, Bayer, and Boehringer Ingelheim. Dr Podolec has received grants and personal fees from Amgen, Terumo, The Medicines Company, AstraZeneca, and Meril. Dr Smits has received personal fees from Terumo and Opsense; has received grants and personal fees from Abbott Vascular, Microport, and Daiichi-Sankyo; and has received grants from SMT and Microport. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors thank Dr Marcel Zwahlen for his advice on the inverse probability-ofcensoring weights modeling-
dc.language.isoen-
dc.publisherELSEVIER SCIENCE INC-
dc.rights2022 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION PUBLISHED BY ELSEVIER-
dc.subject.otherdrug-eluting stent-
dc.subject.otherdual antiplatelet therapy-
dc.subject.otherhigh bleeding risk-
dc.subject.otherP2Y12 inhibitor-
dc.subject.otheracetylsalicylic acid-
dc.titleImpact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy-
dc.typeJournal Contribution-
dc.identifier.epage778-
dc.identifier.issue8-
dc.identifier.spage766-
dc.identifier.volume80-
local.format.pages13-
local.bibliographicCitation.jcatA1-
dc.description.notesValgimigli, M (corresponding author), Univ Svizzera Italiana USI, Cardioctr Inst, Ente Osped Cantonale, CH-6900 Lugano, Switzerland.-
dc.description.notesmarco.valgimigli@eoc.ch-
local.publisher.placeSTE 800, 230 PARK AVE, NEW YORK, NY 10169 USA-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1016/j.jacc.2022.04.065-
dc.identifier.pmid35981821-
dc.identifier.isi000863530300004-
dc.contributor.orcidLee, Astin/0000-0002-0199-8365; Heg, Dik/0000-0002-8766-7945; Schultz,-
dc.contributor.orcidCarl/0000-0002-0847-4361-
local.provider.typewosris-
local.description.affiliation[Valgimigli, Marco] Univ Svizzera Italiana USI, Cardioctr Inst, Ente Osped Cantonale, CH-6900 Lugano, Switzerland.-
local.description.affiliation[Frigoli, Enrico; Heg, Dik] Univ Bern, CTU Bern, Bern, Switzerland.-
local.description.affiliation[Vranckx, Pascal] Hasselt Univ, Dept Cardiol & Crit Care Med, Hartctr Hasselt, Jessa Ziekenhuis, Hasselt, Belgium.-
local.description.affiliation[Vranckx, Pascal] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium.-
local.description.affiliation[Ozaki, Yukio] Fujita Hlth Univ, Sch Med, Dept Cardiol, Toyoake, Aichi, Japan.-
local.description.affiliation[Morice, Marie-Claude] Cardiovasc European Res Ctr CERC, Massy, France.-
local.description.affiliation[Morice, Marie-Claude] ICPS Ramsay Gen Sante, Massy, France.-
local.description.affiliation[Chevalier, Bernard] Ramsay Gen Sante, Intervent Cardiol Dept, Inst Cardiovasc Paris Sud, Massy, France.-
local.description.affiliation[Onuma, Yoshinobu] Natl Univ Ireland, Galway, Ireland.-
local.description.affiliation[Windecker, Stephan] Bern Univ Hosp, Dept Cardiol, Bern, Switzerland.-
local.description.affiliation[Delorme, Laurent] Clin Pont Chaume, Cardiol & Malad Vasc, AIHP ACCAHP, Montauban, France.-
local.description.affiliation[Kala, Petr] Univ Hosp Brno, Brno, Czech Republic.-
local.description.affiliation[Kala, Petr] Masaryk Univ, Med Fac, Brno, Czech Republic.-
local.description.affiliation[Kedev, Sasko] Univ St Cyril & Methodius, Med Fac, Univ Clin Cardiol, Skopje, North Macedonia.-
local.description.affiliation[Abhaichand, Rajpal K.] G Kuppuswamy Naidu Mem Hosp, Coimbatore, Tamil Nadu, India.-
local.description.affiliation[Velchev, Vasil] Sofia Med Univ, Cardiol Clin, St Anna Univ Hosp Sofia, Sofia, Bulgaria.-
local.description.affiliation[Dewilde, Willem] Imelda Hosp, Bonheiden, Belgium.-
local.description.affiliation[Podolec, Jakub] Jagiellonian Univ Med Coll, Inst Cardiol, Dept Intervent Cardiol, Krakow, Poland.-
local.description.affiliation[Podolec, Jakub] John Paul 2 Hosp, Krakow, Poland.-
local.description.affiliation[Leibundgut, Gregor] Cantonal Hosp Baselland, Cardiol, Liestal, Switzerland.-
local.description.affiliation[Topic, Dragan] Inst Cardiovasc Dis Dedinje, Dept Invas Diagnost & Therapy, Belgrade, Serbia.-
local.description.affiliation[Schultz, Carl] Univ Western Australia, Dept Cardiol, Royal Perth Hosp Campus, Perth, WA, Australia.-
local.description.affiliation[Stankovic, Goran] Univ Belgrade, Clin Ctr Serbia, Dept Cardiol, Belgrade, Serbia.-
local.description.affiliation[Stankovic, Goran] Univ Belgrade, Fac Med, Belgrade, Serbia.-
local.description.affiliation[Lee, Astin] Wollongong Hosp, Dept Cardiol, Wollongong, NSW, Australia.-
local.description.affiliation[Johnson, Thomas] Univ Hosp Bristol, Bristol, Avon, England.-
local.description.affiliation[Johnson, Thomas] Weston NHS Fdn Trust, Bristol, Avon, England.-
local.description.affiliation[Tonino, Pim A. L.] Catharina Hosp, Dept Cardiol, Eindhoven, Netherlands.-
local.description.affiliation[Klotzka, Aneta; Lesiak, Maciej] Univ Med Sci, Dept Cardiol 1, Poznan, Poland.-
local.description.affiliation[Lopes, Renato D.] Duke Univ, Duke Clin Res Inst, Sch Med, Durham, NC USA.-
local.description.affiliation[Smits, Pieter C.] Maasstad Hosp, Dept Cardiol, Rotterdam, Netherlands.-
local.uhasselt.internationalyes-
item.validationecoom 2023-
item.contributorValgimigli, Marco-
item.contributorFrigoli, Enrico-
item.contributorVRANCKX, Pascal-
item.contributorOzaki, Yukio-
item.contributorMorice, Marie-Claude-
item.contributorChevalier, Bernard-
item.contributorOnuma, Yoshinobu-
item.contributorWindecker, Stephan-
item.contributorDelorme, Laurent-
item.contributorKala, Petr-
item.contributorKedev, Sasko-
item.contributorAbhaichand, Rajpal K.-
item.contributorVelchev, Vasil-
item.contributorDewilde, Willem-
item.contributorPodolec, Jakub-
item.contributorLeibundgut, Gregor-
item.contributorTopic, Dragan-
item.contributorSchultz, Carl-
item.contributorStankovic, Goran-
item.contributorLee, Astin-
item.contributorJohnson, Thomas-
item.contributorTonino, Pim A. L.-
item.contributorKlotzka, Aneta-
item.contributorLesiak, Maciej-
item.contributorLopes, Renato D.-
item.contributorSmits, Pieter C.-
item.contributorHeg, Dik-
item.accessRightsOpen Access-
item.fullcitationValgimigli, Marco; Frigoli, Enrico; VRANCKX, Pascal; Ozaki, Yukio; Morice, Marie-Claude; Chevalier, Bernard; Onuma, Yoshinobu; Windecker, Stephan; Delorme, Laurent; Kala, Petr; Kedev, Sasko; Abhaichand, Rajpal K.; Velchev, Vasil; Dewilde, Willem; Podolec, Jakub; Leibundgut, Gregor; Topic, Dragan; Schultz, Carl; Stankovic, Goran; Lee, Astin; Johnson, Thomas; Tonino, Pim A. L.; Klotzka, Aneta; Lesiak, Maciej; Lopes, Renato D.; Smits, Pieter C. & Heg, Dik (2022) Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy. In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 80 (8) , p. 766 -778.-
item.fulltextWith Fulltext-
crisitem.journal.issn0735-1097-
crisitem.journal.eissn1558-3597-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy.pdfPublished version872.68 kBAdobe PDFView/Open
Show simple item record

WEB OF SCIENCETM
Citations

6
checked on Jul 18, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.